Osteoporozda Medikal Tedavi ve Yeni Seçenekler
Osteoporoz kemik kırılganlığında artış ile karekterize oldukça yaygın kas iskelet sistemi
hastalığıdır. Tedavide amaç; kırıkların önlenmesi, kemik mineral yoğunluğunun artırılması,
kırıklara bağlı deformitelerin azaltılması ve yaşam kalitesinin yükseltilmesidir.
Osteoporoz tedavisinde kullanılan birçok ilaç vardır. Önemli olan doğru hastada ideal
ilaçı secmektir.
___
- 1. Eskiyurt N. Osteoporozdan korunma; genel önlemler (kalsiyum,
d vitamini ve fiziksel aktivite). Turkiye Klinikleri J PM&RSpecial
Topics 2012;5(3):98-103
- 2. Lindsay R., Cosman F. Osteoporosis . In Kasper DL., Fauci
AS., Hauser S. Et al. Harrison’s Principles of Internal Medicine.
19th ed. 2016 2488-2504
- 3. Tuzun S, Eskiyurt N, Akarırmak U, Sarıdoğan M, Şenocak (
Turkish Osteoporosis Society) Incidence of hip fractue and prevalance
of osteoporosis in Turkey: the FRACTURK study. Osteoporos
Int 2012;23(3) :949-55
- 4. Sözen T, Özışık L, Başaran NÇ. An overview and management
of osteoporosis. Eur J Rheumatol. 2017 Mar;4(1):46-56. doi:
10.5152/eurjrheum.2016.048. Epub 2016 Dec 30.
- 5. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall
S, Lindsay R; Clinician's Guide to Prevention and Treatment
of Osteoporosis. Osteoporos Int. 2014 Oct;25(10):2359-81.
- 6. Compston J, Cooper A0, Cooper C, Gittoes N, Gregson C, Harvey
N, Hope S, Kanis JA, McCloskey EV, Poole KES, Reid DM, Selby
P, Thompson F, Thurston A, Vine N; National Osteoporosis Guideline
Group (NOGG). UK clinical guideline for the prevention and
treatment of osteoporosis. Arch Osteoporos. 2017 Dec;12(1):43
- 7. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley
DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS,
Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB.
Amerıcan Assocıatıon Of Clınıcal Endocrınologısts And Amerıcan
College Of Endocrınology Clınıcal Practıce Guıdelınes
For The Dıagnosıs And Treatment Of Postmenopausal Osteoporosıs
- 2016. Endocr Pract. 2016 Sep 2;22(Suppl 4):1-42.
- 8. Gamze Kılıç, Salih Özgöçmen. Osteoporozda Medikal Tedavi
Turkiye Klinikleri J PM&R-Special Topics 2012;5(3):104-18
- 9. O'Connor KM. Evaluation and Treatment of Osteoporosis. Med Clin
North Am. 2016 Jul;100(4):807-26. doi: 10.1016/j.mcna.2016.03.016
- 10. Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke
BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ,
Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE. Managing
Osteoporosis in Patients on Long-Term Bisphosphonate Treatment:
Report of a Task Force of the American Society for Bone
and Mineral Research. J Bone Miner Res. 2016 Jan;31(1):16-35
- 11. Osteoporoz ve metabolik kemik hastalıkları tanı ve tedavi klavuzu
2016, Türkiye Endokrinoloji ve Metabolizma Derneği
12. Costa AG, Bilezikian JP. How Long to Treat with Denosumab.
Curr Osteoporos Rep. 2015 Dec;13(6):415-20. Review.
- 13. Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen
EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell
R, Zillikens MC. Discontinuation of Denosumab therapy
for osteoporosis: A systematic review and position statement
by ECTS. Bone. 2017 Aug 5;105:11-17
- 14. Scaglione M, Fabbri L, Casella F, Guido G. Strontium ranelate
as an adjuvant for fracture healing: clinical, radiological,
and ultrasound findings in a randomized controlled study
on wrist fractures. Osteoporos Int. 2016 Jan;27(1):211-8
- 15. Silva GA, Bertassoli BM, Sousa CA, Albergaria JD, de Paula
RS, Jorge EC. Effects of strontium ranelate treatment on osteoblasts
cultivated onto scaffolds of trabeculae bovine bone.
J Bone Miner Metab. 2017 Mar 20.
- 16.Wells G, Chernoff J, Gilligan JP, Krause DS. Does salmon calcitonin
cause cancer? A review and meta-analysis. Osteoporos
Int. 2016 Jan;27(1):13-9.
- 17. Sindel D. Günümüzde ve Gelecekte osteoporoz tedavisi. Türk
Fiz Tıp Rehab Derg 2013;59:330-7
- 18. Abdelazim IA, Abdelrazak KM, Al-Kadi M, Yehia AH, Nusair
BM, Faza MA. Effect of raloxifene hydrochloride on bone
mineral density and bone turnover in Kuwaiti postmenopausal
women with osteoporosis. Arch Osteoporos. 2014;9:189
- 19. Gonnelli S, Caffarelli C. Abaloparatide. Clin Cases Miner Bone
Metab. 2016 May-Aug;13(2):106-109
- 20. Chew CK, Clarke BL. Abaloparatide: Recombinant human
PTHrP (1-34) anabolic therapy for osteoporosis. Maturitas.
2017 Mar;97:53-60
- 21. FDA approves Radius Health's TYMLOS™ (abaloparatide), a bone
building agent for the treatment of postmenopausal women with osteoporosis
at high risk for fracture [press release].Waltham,MA Radius
Health. http://investors.radiuspharm.com/releasedetail.cfm?ReleaseID=
1023557. Published April 28, 2017. Accessed May 9, 2017.
- 22. Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP,
Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK,
Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler
D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR,
Grauer A. Romosozumab (sclerostin monoclonal antibody) versus
teriparatide in postmenopausal women with osteoporosis transitioning
from oral bisphosphonate therapy: a randomised, open-label,
phase 3 trial. Lancet. 2017 Jul 26. pii: S0140-6736(17)31613-6.
- 23. Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox
J, Fan M, Chen L, Grauer A. Romosozumab increases bone
mineral density in postmenopausal Japanese women with osteoporosis:
A phase 2 study. Bone. 2017 Oct;103:209-215
- 24. de Villiers TJ. The quest for new drugs to prevent osteoporosis-
related fractures. Climacteric. 2017 Apr;20(2):103-106